Open access · US-GOV via ClinicalTrials.gov Clinical trial

Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation

Authors not listed

University of Pennsylvania · 2010

Stem-cell exhaustion Altered intercellular communication Stem-cell therapy Human Randomized controlled trial

Abstract

The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-04 MST

Cite this

APA

Anonymous. (2010). Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation. <em>University of Pennsylvania</em>. https://clinicaltrials.gov/study/NCT01551043

Vancouver

Anonymous. Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation. University of Pennsylvania. 2010.

BibTeX

@misc{anon2010PilotS, title = {Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation}, author = {Anonymous}, journal = {University of Pennsylvania}, year = {2010}, }